# Benjamin Kreitman

> Benjamin Kreitman is a seed investor at Broadview Ventures backing Biotechnology and Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures)
- Location: Boston, United States
- Total investments: 5
- Last investment: Dec 2024
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/benjaminkreitman/

Benjamin Kreitman is a seed investor at Broadview Ventures in Boston focused on Biotechnology and Medical. Benjamin Kreitman broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.Prior to joining Broadview, Benjamin was a Consultant at Monitor Deloitte, the strategy management consultingarm of Deloitte Consulting, LLP. At Monitor Deloitte, Benjamin worked alongside senior executives on a variety of engagements including commercial strategy development for biotechnology startups as well as global pharmaceutical and medical device manufacturers, and corporate development and investment due diligence across a number of industries.Benjamin earned undergraduate degrees in Biological Sciences and Financial Economics Magna Cum Laude from Columbia University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Genetics | 1 | 20% |
| Biopharma | 1 | 20% |
| Health Care | 1 | 20% |

8 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 1 | 20% |
| United Kingdom | 1 | 20% |
| The Netherlands | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Alveron Pharma | Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of intracranial hemorrhage. As an injection solution that is ready to use, OKL-1111 is being developed to do away with a laborious pre-treatment process. | $5.3M | Seed | Dec 06, 2024 |  |
| IsomAb | IsomAb evaluate and develop isoform specific antibodies to treat disease. | $9.5M | Seed | Feb 20, 2024 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $5M | Seed | Feb 09, 2022 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. | $20.1M | Seed | May 20, 2021 |  |
| HAYA Therapeutics | HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome. The company leverages its proprietary platform to uncover new insights into disease-associated cell states and the long non-coding RNAs (lncRNAs) that control them. Its lead candidate, HTX-001, is being developed as a potentialtreatment for heart failure. In addition, the company is advancing a pipeline of precision therapies that target lncRNAs for cell-specific treatment of conditions affecting other tissues. |  | Seed |  |  |

5 of 5 investments shown.

## Co-investors
- [4See Ventures](https://shizune.co/investors/profile/4see-ventures) — VC Fund, 2 deals together
- [Apollo Health Ventures](https://shizune.co/investors/profile/apollo-health-ventures) — VC Fund, 2 deals together
- [Bernina BioInvest](https://shizune.co/investors/profile/bernina-bioinvest) — VC Fund, 2 deals together
- [Schroder Adveq](https://shizune.co/investors/profile/schroder-adveq) — VC Fund, 2 deals together
- [SCVC](https://shizune.co/investors/profile/science-creates-ventures) — VC Fund, 2 deals together
- [Viva BioInnovator](https://shizune.co/investors/profile/viva-biotech) — VC Fund, 2 deals together

## About Broadview Ventures

VC Fund · Boston, United States

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

5 contacts available at Broadview Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Benjamin Kreitman | Principal | https://shizune.co/investors/profile/benjamin-kreitman |
| Christopher de Souza | Director | https://shizune.co/investors/profile/christopher-de-souza |
| Daniel Gottlieb | Director | https://shizune.co/investors/profile/daniel-gottlieb-b5a0 |
| Maria Berkman | Director | https://shizune.co/investors/profile/maria-berkman |
| Nichole Schiffer | Director of Operations | https://shizune.co/investors/profile/nichole-schiffer |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Benjamin Kreitman invest in?

Benjamin Kreitman invests primarily in Biotechnology, Medical and Genetics startups, most often at Seed stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Benjamin Kreitman last invest?

The most recent investment recorded for Benjamin Kreitman closed in Dec 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co